Press Room

November 8, 2009

The US Food and Drug Administration has awarded FEFA the contract to provide the development of a web-based, metadata driven software tool for clinical protocol review.  This tool will be utilized by FDA officials to provide specialized and standardized support during the process of reviewing clinical protocols which are filed as part of the investigational new drug application.  The software tool which will be created by FEFA developers will be a unique web based tool which will include database collection and report generation features.

August 1, 2009

FEFA has been awarded a contract to provide 508 compliance services to the US Food and Drug Administration.  Section 508 of the Rehabilitation Act of 1973, as amended by the Workforce Investment Act of 1998, requires that when Federal agencies procure, develop, maintain, or use electronic information technology, they ensure that Federal employees and members of the public with disabilities have access to and use of information and data that is comparable to the access and use of information and data that is available to individuals without disabilities.

FEFA’s team of 508 compliance specialist will convert various documents for the FDA’s Center for Drug Evaluation and Research (CDER) to ensure they are fully accessible to those with disabilities. This includes documents appearing on CDER’s Intranet and Internet along with Word, Abode PDF, e-mail, PowerPoint, Excel, other media formats, and web pages.

Web accessibility means that people with disabilities have equal access to all Web sites (Intranet and Internet) and attached files. More specifically, Web accessibility means that people with disabilities can perceive, understand, navigate, and interact with the Web, and that they can contribute to the Web. Standards for accessibility of web-based information are promulgated by the US Access Board.

Please Contact the FEFA, Inc. offices at:
1700 Rockville Pike; Suite 400
Rockville, MD 20852
301.998.6584 (v) 202.521.1808 (f)

This e-mail address is being protected from spambots. You need JavaScript enabled to view it